The amino acid profile in blood plasma of young boys with autism

Bugajska, Jolanta; Berska, Joanna; Wojtyto, Tomasz; Bik-Multanowski, Mirosław; Sztefko, Krystyna

doi:10.12740/pp/65046

Cited by 20 publications

(19 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two other studies were found to only lack correction for multiple hypothesis testing (Naushad et al, 2013; Zaki et al, 2017). Five identified studies were affected by two of the aforementioned limitations (Shimmura et al, 2011; Tu et al, 2012; Hassan et al, 2013; Kuwabara et al, 2013; Bugajska, Berska, Wojtyto, Bik-Multanowski, & Sztefko, 2017), and three others were limited by three of these study design challenges (Tirouvanziam et al, 2011; ElBaz, Zaki, Youssef, ElDorry, & Elalfy, 2014; Bala et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…However, our sample size is still more than double that of most similar studies. For example, other recent studies have used cohort sample sizes of 23 ASD and 22 TD (Shimmura et al, 2011); 27 ASD and 20 TD (Tirouvanziam et al, 2011); 20 ASD and 20 TD (Tu et al, 2012); 10 ASD and 10 TD (Hassan et al, 2013); 25 ASD and 28 TD (Kuwabara et al, 2013); 20 ASD and 20 TD (ElBaz et al, 2014); 20 ASD and 19 TD (El-Ansary & Al-Ayadhi, 2014); 21 ASD and 21 TD (Bala et al, 2016); 20 ASD and 20 TD (El-Ansary, 2016); 42 ASD and 26 TD (Zaki et al, 2017); and 27 ASD and 13 TD (Bugajska et al, 2017). While some studies do have similar or larger sample sizes, such as with 55 ASD and 44 TD (Adams et al, 2011); 138 ASD and 138 TD (Naushad et al, 2013); or 51 ASD and 51 TD (Cai et al, 2016), there are many more studies with small sample sizes than with comparable ones.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Investigating plasma amino acids for differentiating individuals with autism spectrum disorder and typically developing peers

Vargason

Krüger

McGuinness

et al. 2018

Research in Autism Spectrum Disorders

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Investigating plasma amino acids for differentiating individuals with autism spectrum disorder and typically developing peers

Vargason

Krüger

McGuinness

et al. 2018

Research in Autism Spectrum Disorders

View full text Add to dashboard Cite

show abstract

“…The details of 22 observational studies are displayed in Table 1. Four studies were conducted in Asia (48‐51), three studies in Europe (31,52,53), four studies in the Middle East (23,33‐34,54), 10 studies in North America (6‐7,17,21‐22,29,32,55‐57), and 1 study in South America (58). These studies were published between 1995 (53) and 2019 (51), with all but 1 study (53) published after the year 2000.…”

Section: Resultsmentioning

confidence: 99%

Blood biomarker levels of methylation capacity in autism spectrum disorder: a systematic review and meta‐analysis

Guo

Ding

2020

Acta Psychiatr Scand

View full text Add to dashboard Cite

Blood biomarker levels of methylation capacity in autism spectrum disorder: a systematic review and meta-analysis Guo B-Q, Ding S-B, Li H-B. Blood biomarker levels of methylation capacity in autism spectrum disorder: a systematic review and metaanalysis.Objective: To compare the peripheral blood levels of methionine (Met), S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), and the SAM/SAH ratio (the most core and predictive indices of cellular methylation ability) between patients with autism spectrum disorder (ASD) and control subjects. Methods: PubMed, Embase, PsycINFO, Web of Science, and Cochrane Library were searched from inception to August 2, 2019, without language restriction. The random-effects model was used to summarize effect sizes. Results: We retrieved 1,493 records, of which 22 studies met inclusion criteria. Our overall analyses revealed that individuals with ASD had significantly decreased levels of Met (22 studies; Hedges' g = À0.62; 95% confidence interval [CI]: À0.89, À0.35), SAM (8 studies; Hedges' g = À0.60; 95% CI: À0.86, À0.34), and the SAM/SAH ratio (8 studies; Hedges' g = À0.98; 95% CI: À1.30, À0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94). The findings of the overall analyses were quite stable after being verified by sensitivity analyses and in agreement with the corresponding outcomes of subgroup analyses. Additionally, our results from metaanalytic techniques confirmed that the effect estimates of this metaanalysis did not originate from publication bias. Conclusion: Individuals with ASD have substantially aberrant peripheral blood levels of Met, SAM, SAH, and the SAM/SAH ratio, which supports the association between impaired methylation capacity and ASD. Therefore, further investigations into these indices as potential biomarkers for diagnosis and therapeutic targets of ASD are warranted. Summations• Individuals with ASD had significantly decreased blood levels of Met, SAM, and the SAM/SAH ratio.• Individuals suffering from ASD had significantly increased blood levels of SAH. • These findings support the association between impaired methylation capacity and ASD. Limitations• The number of studies that analyzed the blood levels of SAM, SAH, and the SAM/SAH ratio in ASD patients was relatively small.• We were unable to exhaustively explore the underlying causes that accounted for the heterogeneity in this meta-analysis.• There were obvious differences in the laboratory operating processes for the analysis of blood samples among studies.

show abstract

“…Yuan et al [23] revealed that decreased GABA level and increased Asp, Glu, Tau, and l-Ser levels in plasma could be correlated with Parkinson's disease. Bugajska et al [24] found a correlation between low plasma exogenous AA levels and autism in a pediatric population, so that there may be a correlation between autism and phenylketonuria [25]. Zaki et al [26] found that the levels of some AAs in autistic children, other than Phe in plasma, differed from those in healthy children.…”

Section: Discussionmentioning

confidence: 99%

Plasma amino acid levels in a cohort of patients in Turkey with classical phenylketonuria

Kazanasmaz

Karaca

2020

Asian Biomedicine

View full text Add to dashboard Cite

BackgroundIn patients with phenylketonuria, the central nervous system is adversely affected by noncompliance with diet. The levels of phenylalanine and many different amino acids (AAs) in the plasma of patients with phenylketonuria can be measured simultaneously.ObjectivesTo measure the blood plasma levels of neurotransmitter AAs in a cohort of patients in Sanliurfa province, Turkey, with phenylketonuria for use as a support parameter for the follow-up of patients.MethodsThe phenylketonurics that we followed (n = 100) were divided into 2 groups according to their compliance with their dietary treatment. Plasma AA analysis results of phenylketonurics were compared with those of healthy children in a control group (n = 50).ResultsIn the diet incompliant group (n = 56), the mean levels of γ-aminobutyric acid (GABA; 0.96 ± 1.07 μmol/L) and glycine (305.1 ± 105.19 μmol/L) were significantly higher than those in the diet compliant group (n = 44; GABA P = 0.005, glycine P < 0.001) and in the control group (GABA and glycine P < 0.001), whereas the mean levels of glutamic acid (39.01 ± 22.94 μmol/L) and asparagine (39.3 ± 16.89 μmol/L) were lower (P < 0.001) in the diet incompliant group. A positive correlation was observed between the levels of phenylalanine and GABA and glycine. A negative relationship was found between the levels of phenylalanine and glutamic acid and asparagine.ConclusionsA relationship exists between the levels of plasma phenylalanine in a cohort of phenylketonurics in Sanliurfa province, Turkey, and the levels of some excitatory and inhibitory AAs. Excitatory and inhibitory AA levels in plasma may be used as support parameters in the follow-up of patients with phenylketonuria.

show abstract

The amino acid profile in blood plasma of young boys with autism

Abstract: Lower levels of exogenous amino acids confirm the possible role of these amino acids in autism. Determination of exogenous amino acids in plasma, however, cannot be used as a diagnostic test but it can still support autistic patients care.

Cited by 20 publications

References 26 publications

Investigating plasma amino acids for differentiating individuals with autism spectrum disorder and typically developing peers

Investigating plasma amino acids for differentiating individuals with autism spectrum disorder and typically developing peers

Blood biomarker levels of methylation capacity in autism spectrum disorder: a systematic review and meta‐analysis

Plasma amino acid levels in a cohort of patients in Turkey with classical phenylketonuria

Contact Info

Product

Resources

About